Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial

JOURNAL ARTICLE published 1 December 2016 in Anticancer Research

Authors: CESARE GRIDELLI | ANTONIO CHELLA | GIUSEPPE VALMADRE | GIACOMO ALLEGRINI | MATTEO BRIGHENTI | PAOLO BIDOLI | ANTONIO ROSSI | PAOLO MAIONE | MARIA RITA MIGLIORINO | SERENA RICCIARDI | FILIPPO DE MARINIS